<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865082</url>
  </required_header>
  <id_info>
    <org_study_id>2125-MST-206</org_study_id>
    <nct_id>NCT03865082</nct_id>
  </id_info>
  <brief_title>Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)</brief_title>
  <official_title>Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotheraphy
      drugs ipilimumab and nivolumab in different solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, global, multi-center, multicohort study of intratumoral
      tilsotolimod in combination with nivolumab and ipilimumab for the treatment of specific solid
      tumors
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate the efficacy of intratumoral tilsotolimod in combination with ipilimumab and nivolumab for each cohort</measure>
    <time_frame>ORR defined as a CR or partial response (PR) according to RECIST v1.1, confirmed by imaging ≥ 4 weeks after the initial documentation of response (to occur up to 24 months).</time_frame>
    <description>Efficacy measure by overall response rate (ORR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the combination of tilsotolimod with nivolumab and ipilimumab</measure>
    <time_frame>At every study visit (up to 48 months)</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms(ECGs), safety and laboratory parameters as assessed by CTCAE v4.03 or higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate serum concentrations of tilsotolimod, nivolumab, and ipilimumab using sparse blood sampling</measure>
    <time_frame>Screening, Day -7, Cycle 1 Day 1 and Cycle 3 Day 1 (up to 17 weeks). Each cycle is 28 days</time_frame>
    <description>Serum concentrations will be determined for tilsotolimod, nivolumab, and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of tilsotolimod in combination with nivolumab and ipilimumab</measure>
    <time_frame>Screening, Day -7, Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1 and Cycle 7 Day 1, (up to 32 weeks). Each cycle is 28 days</time_frame>
    <description>Anti-drug anitbody measures of tilsotolimod when combined with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tilsotolimod by intratumoral injection plus Nivolumab and Ipilimumab intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilsotolimod</intervention_name>
    <description>9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Day -7 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>IMO-2125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Subject ≥ 18 years of age (males and females)

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 minimum life
             expectancy ≥ 4 months, adequate organ functions, and ≥1 lesion accessible for
             intratumoral injection and biopsy(ies).

          3. Women of child bearing potential (WOCBP) and men with WOCBP partners must agree to use
             effective contraception methods as defined I n the clinical study protocol.

        Inclusion Criteria ( MSS CRC IO Naïve)

          1. Histologically confirmed advanced, metastatic, or progressive MSS CRC based on either
             an analysis of tissue from a prior biopsy or based on tissue from a new biopsy.
             Subject's microsatellite/MMR status should be known.

          2. Received at least two prior regimens of therapy for advanced or metastatic CRC
             including fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Subjects who
             relapse within 6 months of adjuvant chemotherapy composed of oxaliplatin and a
             fluoropyrimidine will have their adjuvant therapy count as one prior regimen.

          3. Documentation of radiologic progression by Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1 during or after previous chemotherapy.

        Main Exclusion Criteria:

          1. Subject must have completed or completely discontinued any previous cancer-related
             treatments before enrollment with necessary windows and wash out periods as defined in
             the clinical study protocol.

          2. History of interstitial lung disease, pneumonitis, known or suspected autoimmune
             diseases (unless for specific diseases as defined in protocol) or human
             immunodeficiency virus (HIV) infection.

          3. Prior therapy with TLR9 agonist, excluding topical agents.

          4. Known hypersensitivity to any study drug component.

          5. Prior immune-mediated AE of intensity Grade ≥ 3.

          6. Subject with another primary malignancy that has not been in remission for at least 3
             years except for non-melanoma skin cancer, curatively treated localized prostate
             cancer with non-detectable prostate specific antigen, cervical carcinoma in situ on
             biopsy, or thyroid cancer (except anaplastic).

          7. Active systemic infections requiring antibiotics, active Hepatitis A, B or C
             infections.

          8. Women who are breast feeding or pregnant.

          9. Prior anaphylactic or other severe infusion reaction associated with human antibody
             administration that cannot be managed by standard supportive measurements.

         10. Presence of unstable central nervous system disease involvement

         11. Subject with unstable and impaired cardiac function or clinically significant cardiac
             disease per Investigator's clinical judgment.

         12. Has received live attenuated vaccine 30 days before first study dose.

        Exclusion Criteria (MSS CRC IO Naïve):

          1. Prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed cell death
             ligand-1 (PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory
             or co-inhibitory T-cell receptor in an approved or experimental setting.

          2. Subjects with BRAF V600E mutations.

          3. Subjects with a history of immune-mediated colitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medical Center Tucson Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Babiker, MD</last_name>
      <phone>520-694-8888</phone>
      <email>hanibabiker@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California/ Hoag Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz, MD</last_name>
      <phone>323-865-3000</phone>
      <email>lenz@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Overman, MD</last_name>
      <phone>713-792-2828</phone>
      <email>moverman@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael Overman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

